Gastroparesis — delayed gastric emptying causing chronic nausea, vomiting, and early satiety — has historically had very limited pharmacological treatment options, with the Gastrointestinal Therapeutics Market reflecting the anticipated entry of relamorelin and trazpiroben as potential first new gastroparesis pharmacological approvals in decades that could transform management of this debilitating condition.

Current gastroparesis management relies primarily on dietary modification, prokinetic agents with limited efficacy and significant side effects, and antiemetics that address symptoms without improving gastric motility. Metoclopramide — the only FDA-approved gastroparesis drug — carries a black box warning for tardive dyskinesia with chronic use that significantly limits its prescription to ninety days of continuous use, leaving most gastroparesis patients without approved pharmacological options beyond symptom management with unapproved agents.

Relamorelin — a ghrelin receptor agonist stimulating gastric motility through growth hormone secretagogue receptor activation — demonstrated statistically significant improvement in vomiting episodes and gastric emptying rate in Phase II trials for diabetic gastroparesis. Pending Phase III trial outcomes, relamorelin represented one of the most advanced gastroparesis clinical development programs with a plausible mechanism targeting the physiological motility pathway rather than dopaminergic antiemetic mechanisms with tardive dyskinesia risk.

Tradipitant — a selective NK1 receptor antagonist reducing nausea through substance P pathway blockade — demonstrated symptom improvement in gastroparesis Phase II trials with an adverse effect profile superior to prokinetics, with Phase III development examining whether nausea reduction translates to meaningful clinical benefit in gastroparesis patients whose nausea is often the dominant quality-of-life-impacting symptom.

Do you think new gastroparesis pharmacological approvals will finally provide durable treatment options for the large underserved gastroparesis patient population?

FAQ

What medications treat gastroparesis? Metoclopramide is the only FDA-approved gastroparesis medication but has a tardive dyskinesia black box warning limiting continuous use to ninety days; domperidone (not FDA-approved), erythromycin, and antiemetics are commonly used off-label; new agents in development may expand options.

What is ghrelin receptor agonist therapy for gastroparesis? Ghrelin receptor agonists including relamorelin stimulate gastric motility through the growth hormone secretagogue receptor pathway, offering a mechanistic approach to improving gastric emptying rate as a potential gastroparesis treatment without the dopaminergic side effects of prokinetics.

#GastrointestinalTherapeutics #GastroparesisTherapy #Relamorelin #GastricMotility #Prokinetics #GastroparesisManagement